Nordic RBC Group

P-SP420-THAL-01

—

by

Andreas Glenthøj
in
  • Patient group: Transfusion dependent beta-thalassemia
  • Sponsor: Pharmacosmos
  • ID: NCT05693909
  • Details: https://clinicaltrials.gov/study/NCT05693909
  • Trial site: Rigshospitalet, Copenhagen, Denmark
  • Nordic Investigator: Andreas Glenthøj, Rigshospitalet, Copenhagen, Denmark (andreas.glenthoej@regionh.dk)

Congenital dyserythropoietic anemia Spherocytosis Thalassemia Xerocytosis

Comments

Leave a Reply